The patient cohort is consisted of 12 breast cancer cases that treated with a docetaxel-based neoadjuvant chemotherapy of 6-8 courses (average of three weeks per course), including 9 luminal B, 2 HER2+ and 1 TNBC patients. The gene discussed is ERBB2; the disease is breast carcinoma.